Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5393 |
CK1-IN-1
PUN51207 |
p38 MAPK; Casein Kinase | MAPK; Metabolism; Stem Cells |
CK1-IN-1 (PUN51207) 是一种酪蛋白激酶 1 抑制剂,对 CK1δ、CK1ε和p38σ MAPK 的IC50值为 15 nM、16 nM 和73 nM。 | |||
T10827 |
CK2/ERK8-IN-1
TMCB |
Apoptosis; ERK; Casein Kinase; Pim; DYRK | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Metabolism; Stem Cells; Tyrosine Kinase/Adaptors |
CK2/ERK8-IN-1 (TMCB) 是一种酪蛋白激酶 2 (CK2) (Ki 为 0.25 µM) 和 ERK8 (MAPK15, ERK7) 的双重抑制剂,IC50 均为 0.50 μM。CK2/ERK8-IN-1 也与 PIM1,HIPK2 和 DYRK1A 结合,Ki 值分别为 8.65 µM,15.25 µM 和 11.9 µM。 | |||
TQ0255 |
Olafertinib
CK-101,EGFR-IN-3,RX-518 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Olafertinib (RX-518) 是新型突变选择性、不可逆、可口服的EGFR 酪氨酸酶抑制剂,可克服 NSCLC 中 T790M 介导的耐药性。 | |||
T10828 |
CK2/PIM1-IN-1
|
Others | Others |
CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1 (IC50s: 3.787 μM and 4.327 μM). It is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions. | |||
T30953 |
CK 17
CK-17,CK17 |
||
CK-17 is an interleukin-1 antagonist and an IL-1 blocker, which inhibits fibroblast proliferation in a concentration-dependent manner. | |||
T77151 | Cosibelimab | ||
Cosibelimab(CK-301; TG-1501)是一种高亲和力、全人源 PD-L1阻断单克隆抗体,可结合 PD-L1并阻断其与 PD-1的相互作用。Cosibelimab 具有功能性 Fc 结构域,能够诱导 ADCC 和补体依赖性细胞毒性 (CDC) 介导的PD-L1+细胞系杀伤,包括淋巴瘤细胞。 |